Skip to Main Content

Paper Details

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Eur J Cancer
17
2017
Arimidex, HER2, HER2+, HER2+ve cancers, HER2-ve cancers, Patients, Tamoxifen, Tamoxifen Exemestane, aromatase, patient, patients, tamoxifen
Author NameAffiliation
John M S BartlettOntario Institute for Cancer Research (OICR), University Avenue, Canada University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital
Meredith M ReganDana-Farber Cancer Institute, Harvard Medical School
Elizabeth MallonElizabeth University Hospital
Caroline SeynaeveErasmus MC Cancer Institute
Cornelis J H van de VeldeLeiden University Medical Center
Cassandra L BrookesLeicester Clinical Trials Unit, University of Leicester
John F ForbesUniversity of Newcastle, Calvary Mater Newcastle Hospital
Daniel ReaCancer Research UK Clinical Trials Unit, University of Birmingham
  • 1 - 8

Datasets